DAIC

FEBRUARY 2, 2024

Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. This is the most commonly used ablation catheter in the world for RF ablation and is fully integrated with the CARTO 3 System.

Ablation 105

Ablation Atrial Fibrillation AFIB Heart Rhythm 105

HeartRhythm

MARCH 28, 2025

Rhythm control therapy and especially atrial fibrillation (AF) ablation are the focus of growing research in patients with AF. Recent findings suggest that reduction of AF burden mediates the beneficial effects of AF ablation on cardiovascular events and quality of life.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Quality of Life Technology 40

Frontiers in Cardiovascular Medicine

MAY 1, 2024

BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Pulmonary Technology 52

HeartRhythm

SEPTEMBER 23, 2024

Atrial fibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Rhythm Electrophysiology 40

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) catheter ablation trials report arrhythmia-free survival using different post-ablation rhythm monitoring protocols, resulting in difficulties in the interpretation of the recurrence rates and comparison of ablation strategies and technologies.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Arrhythmia 40

DAIC

JUNE 4, 2024

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

HeartRhythm

APRIL 30, 2024

Omnipolar technology near-field (OTNF) is an emerging cardiac mapping approach and may provide insights into electroanatomical substrate mapping during atrial fibrillation (AF) ablation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology 40

DAIC

OCTOBER 21, 2024

FDA approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation System.

Ablation 59

Ablation Atrial Fibrillation Technology Electrophysiology 59

DAIC

JANUARY 29, 2025

16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrial fibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. 2024, May 15).

AFIB 52

AFIB Atrial Fibrillation Quality of Life Heart Rhythm 52

DAIC

JUNE 11, 2024

Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.

Innovation 104

Innovation AFIB Technology Electrophysiology 104

HeartRhythm

APRIL 30, 2024

Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF). PV reconnection is the most common cause of recurrent AF following an ablation procedure.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Technology 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) and very-high power short-duration (vHPSD) radiofrequency ablation are the most recently introduced technologies for atrial fibrillation (AF) ablation. The procedural performance, safety, and effectiveness of PFA versus vHPSD are currently unknown.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology 40

HeartRhythm

AUGUST 21, 2024

No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrial fibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation.

Anatomy 40

Anatomy Atrial Fibrillation Pulmonary Ablation 40

HeartRhythm

SEPTEMBER 9, 2024

Pulsed field ablation (PFA) for the treatment of paroxysmal atrial fibrillation (AF) was validated to be safe and effective.1 Widespread adoption of this potentially transformative technology has brought into the focus the economics of AF with new therapies requiring significant capital and disposable investment.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology 40

HeartRhythm

NOVEMBER 5, 2024

Pulsed field ablation (PFA) is a safe and effective technology for catheter ablation of atrial fibrillation (AF). Multiple PFA-platforms for AF-ablation have been developed. However, evidence comparing the real-word implementation and performance of different PFA-systems is still limited.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Outcomes 40

HeartRhythm

APRIL 30, 2024

The 1st generation HeartLight laser balloon (LB) ablation is highly effective in achieving pulmonary vein isolation (PVI), and the safety and 12-month efficacy are comparable with paroxysmal atrial fibrillation (PAF) ablation technologies.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Pulmonary 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) has recently been introduced as a novel routine ablation technology for paroxysmal atrial fibrillation (AF). It is also used as off-label therapy for persistent AF.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Pulmonary 40

HeartRhythm

APRIL 30, 2024

As an energy source, pulsed field ablation (PFA) has generated tremendous excitement for AF treatment, largely due to its safety profile. All of the PFA technologies in clinical use, or being studied in clinical trials employ microsecond-scale pulses.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology 40

HeartRhythm

APRIL 30, 2024

We have employed digital twin technology to perform extra pulmonary vein (PV) ablation in patients with non-paroxysmal atrial fibrillation (AF). We reported that high dominant frequency (DF) site ablation improved rhythm outcomes, but high maximal slope of action potential restitution curve (Smax) site ablation did not.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Pulmonary 40

HeartRhythm

APRIL 30, 2024

Non-thermal pulsed field ablation (PFA) is an novel technology to perform pulmonary vein isolation (PVI) for atrial fibrillation (AF). Different PFA systems are available, but no comparative data exist.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation Technology 40

HeartRhythm

APRIL 9, 2024

Pulsed field ablation (PFA) is an innovative technology recently adopted for treating atrial fibrillation (AF). Preclinical and clinical studies have reported a reassuring safety profile because of its tissue-specific effect, sparing adjacent tissues.1

Atrial Fibrillation 40

Atrial Fibrillation Ablation Innovation Technology 40

DAIC

JULY 17, 2024

The present invention relates to medical methods for transseptal access to the heart using steerable introducers based on the Company’s Morph DNA technology. This additional patent protection for BioCardia’s current and future products in this important existing market enhances shareholder value.

Myocardial Infarction 105

Myocardial Infarction Atrial Fibrillation Technology Angina 105

DAIC

DECEMBER 26, 2023

a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

Ablation 59

Ablation Atrial Fibrillation Technology Cardiothoracic 59

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2023

This study investigated myocardial injury and inflammation following pulmonary vein isolation using (1) Standard radiofrequency ablation, (2) very high-power short-duration (vHPSD)-70W, (3) vHPSD-90W, and (4) pulsed-field ablation (PFA). Results Baseline characteristics were well-balanced between groups (age 63.1 ± 10.3 ng/L; p  < .001).

Ablation 40

Ablation Atrial Fibrillation Technology Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Catheter ablation of atrial fibrillation (AF) has emerged as the most effective therapy. However, rare anatomical abnormalities such as situs inversus totalis, dextrocardia, or interrupted inferior vena cava can make ablation challenging.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pacemaker Technology 40

Journal of Cardiothoracic Surgery

JANUARY 22, 2025

Pulmonary vein isolation (PVI) with cryoballoon (CB) ablation technology is widely used to treat drug-resistant atrial fibrillation (AF). During CB ablation, there is a possibility of forming an ice cap of con.

Ablation 40

Ablation Atrial Fibrillation Technology Pulmonary 40

Journal of Cardiovascular Electrophysiology

JANUARY 10, 2024

Abstract Introduction Despite advanced ablation strategies and major technological improvements, treatment of persistent atrial fibrillation (AF) remains challenging and the underlying pathophysiology is not fully understood. First, high-density mapping (78% biatrial) with a multipolar mapping catheter was performed.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outpatient Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) has recently been introduced as a novel ablation technology for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). High rates of acute PVI have been observed based on electrograms of the PFA device only.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Technology 40

HeartRhythm

SEPTEMBER 25, 2024

Pulsed field ablation (PFA)-induced electroporation is an application of high-energy, direct-current shocks on myocardium albeit at a considerably lower current density that decreases the risks of arcing and barotrauma.1

Ablation 40

Ablation Atrial Fibrillation Tachycardia Technology 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) is a non-thermal ablation technology, utilising the mechanism of electroporation to interrupt the cellular membrane and induce myocyte apoptosis.

Ablation 40

Ablation Atrial Fibrillation Tachycardia Technology 40

HeartRhythm

APRIL 30, 2024

FDA approval of a laser etched kerfed and irrigated tip catheter to improve catheter stability was based upon bench and efficacy studies among adult patients with atrial fibrillation. The effect of this technology on intralesional catheter stability during accessory pathway (AP) ablation in children is unknown.

Ablation 40

Ablation Atrial Fibrillation Technology 40

HeartRhythm

APRIL 30, 2024

Introduction: Pulsed Field Ablation (PFA) technologies are being studied in a number of clinical trials, many with strict inclusion/exclusion criteria-typically younger patients with less comorbidities undergoing de-novo PVI procedures.

Ablation 40

Ablation Atrial Fibrillation Arrhythmia Technology 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 6, 2024

Characteristics of acute insufficient lesions during vHPSD ablation were analyzed in the retrospective phase. Based on these data, an optimized approach combining both vHPSD ablation and AI-guided ablation was prospectively tested, resulting in an approximately 90% first-pass PVI rate. 0001) with shorter ablation time ( p =.04).

Ablation 40

Ablation Atrial Fibrillation Technology Pulmonary 40

HeartRhythm

MAY 15, 2024

In the past decade, major advances were made in catheter ablation for arrhythmias and implantation of cardiac implantable electronic devices.1 1 Catheter ablation for atrial fibrillation (AF) and ventricular tachycardia (VT) has become the standard of care for many patients presenting with these arrhythmias.2–4

Electrophysiology 40

Electrophysiology Atrial Fibrillation Ablation Arrhythmia 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Data comparing PFA to VHPSD-PVI is lacking. Two tamponades occurred in the PFA while in VHPSD two pts suffered groin bleedings.

Ablation 40

Ablation Pulmonary Arrhythmia Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

MARCH 4, 2024

This information allows more focused intracardiac mapping (activation map during VT, center figure) and accelerates the ablation process, reducing time to first ablation, overall procedure duration (right figure), and fluoroscopy use. reduction in time to ablation (133 ± 48 vs. 165 ± 49 min, p  = 0.02), a 22.6% vs. 33.2 ± 18.0

Arrhythmia 40

Arrhythmia Ablation Tachycardia Atrial Fibrillation 40

DAIC

MARCH 26, 2024

The most common arrhythmia, atrial fibrillation , will affect approximately 12.1 Food and Drug Administration (FDA) in July 2023, a new leadless pacemaker system placed in both chambers of the heart and using a novel communication technology is now offering a more minimally invasive option for patients. Approved by the U.S.

Pacemaker 105

Pacemaker Heart Rhythm Arrhythmia Atrial Fibrillation 105